Renal: Chronic Kidney Disease (CKD)

Percentage of calendar months within a 12-month period during which a hemoglobin level is measured for patients aged 18 years and older with a diagnosis of advanced chronic kidney disease (CKD) (stage 4 or 5, not receiving Renal Replacement Therapy [RRT]) or End Stage Renal Disease (ESRD) (who are on hemodialysis or peritoneal dialysis) who are also receiving erythropoiesis-stimulating agent (ESA) therapy have a hemoglobin level > 12.0 g/dL

Percentage of patients aged 18 years and older with a diagnosis of chronic kidney disease (CKD) (stage 3, 4, or 5, not receiving Renal Replacement Therapy [RRT]) who had a fasting lipid profile performed at least once within a 12-month period

To ensure that members with chronic kidney disease (CKD), but who are not on dialysis, are monitored for blood calcium levels at least annually.

To ensure that members with chronic kidney disease are monitored for PTH levels at least once annually.

To ensure that members with chronic kidney disease (CKD) who are not on dialysis are monitored for blood phosphorus levels at least once annually.

The percentage of patients with chronic kidney disease that have been screened for dyslipidemia with a lipid profile.

The percentage of patients with chronic kidney disease stage 5 and an LDL greater than or equal to 130 mg/dl that have a current refill for a lipid lowering agent.

The Delay in Progression of CKD Measure is an outcome measure to assess how well providers delay progression from Stage 4 CKD to end-stage renal disease (ESRD) requiring chronic dialysis.

Percentage of all adult peritoneal dialysis and hemodialysis patients included in the sample for analysis with serum calcium measured at least once within month

The percentage of patients aged 18 years and older with proteinuria who are taking an angiotensin converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB)